Keppra

Levetiracetam, the active ingredient in Keppra, is an anticonvulsant presented as an oral tablet for oral use. It is employed to control various types of epileptic seizures in adult and pediatric patients. GNH USA supplies Keppra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is indicated for the management of several seizure disorders within the broader epilepsy therapeutic area. - Partial onset seizures: Reduces the frequency of focal seizures in patients with epilepsy. - Myoclonic seizures: Controls sudden, brief muscle jerks associated with myoclonic epilepsy. - Primary generalized tonic‑clonic seizures: Decreases the occurrence of generalized convulsive seizures in both adults and children.

Levetiracetam may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: A sensation of light‑headedness or unsteadiness. - Somnolence: Increased sleepiness or fatigue during the day. - Headache: Mild to moderate pain in the head region. - Nausea: Feeling of stomach upset or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reactions: Including rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: Rare but serious skin disorder with blistering. - Suicidal thoughts or severe depression: Mood changes requiring immediate medical attention.

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal function: Adjust dosage in patients with impaired renal clearance. - Psychiatric history: Monitor for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: Use caution when combined with other sedating agents. - Pregnancy: Evaluate risk‑benefit ratio as safety data are limited. - Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: May lower levetiracetam plasma concentrations. - Phenobarbital: Can reduce levetiracetam levels, decreasing seizure control. - Phenytoin: May decrease levetiracetam exposure, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Alcohol: May enhance central nervous system depression and dizziness. - Other antiepileptics: Potential additive effects on sedation or seizure threshold. - Hormonal contraceptives: Levetiracetam may reduce contraceptive effectiveness, requiring additional protection.